Kornimate/medical-research-clean huggingface dataset:
effects of tart cherry juice on the body

Conditions: Cardiovascular Risk Factors; Age-Related Cognitive Decline

Summary: tart cherries are a rich source of antioxidants. studies have shown that tart cherries exert anti-oxidative and anti-inflammatory properties. the purpose of this study is to learn about the effects of drinking tart cherry juice on cardiovascular and cognitive health.

thirty-seven older adults were randomly assigned to drink 16 oz per day of either tart cherry juice or placebo drink for 12 weeks. blood and urine samples were collected at baseline and 12 weeks to assess biomarkers. physical activity and 3-day diet records were also collected throughout the study.

Eligibility criteria:
inclusion criteria: • age 65-80 exclusion criteria: * allergic to tart cherries * heavy smoker * taking medications that affect cognitive function * history of neurological disorders * history of traumatic brain injury * history of stroke * clinical diagnosis of diabetes * clinical diagnosis of alzheimer's disease/dementia * gi disease * kidney disease * liver disease * cancer
the effects of lower extremity sensory retraining treatment in individuals with post-stroke sensory impairment

Conditions: Stroke; Sensory Deficits

Summary: background: it is estimated that 50%-85% of individuals post stroke demonstrate sensory deficits. sensory impairments are often overlooked in the therapeutic setting, although they lead to slower motor recovery. working hypothesis: the overall goal of this study is to examine the effectiveness of a sensory discrimination reeducation oriented therapeutic program to the lower limb of stroke patients with sensory impairments. we assume that subjects to both groups will make progress, which will be more significant in the experimental group. methods: study population and design: sixty individuals with chronic sensory impairment following a stroke will be recruited. patients will be randomly assigned to sensory retraining treatment or to sensory stimulation treatment. treatment will consist of ten 45 minute long intervention sessions, carried out within a 6 weeks period, and a home exercise program. the person conducting the assessments will be blind to the treatment allocation of the subjects. outcome measures: the efficacy of the intervention will be determined in relation to the international classification of functionality (icf) developed by the world health organization and will include assessments at the three domains defined by this model: 1. body structure and function - determined by measures of the sensory capacity of the lower more affected limb; 2. activities - determined by measures of balance and gait; 3. participation - determined by measures of well-being and social reintegration. two new outcome measures, for ankle and knee position sense and for texture discrimination of the foot, will be developed within this study. data reliability measures on healthy population, and test - retest measures in post stroke population with be collected. intervention: the experimental group will be treated by a perception learning oriented protocol for sensory reeducation, to improve identification, localization and discrimination of sensory stimuli, including electrical stimulation, texture and hardness discrimination and position sense training. the control group will receive the same stimuli without the attentive learning and discriminating component. importance: scientific proof and focused recommendations for a potent therapeutic method for the post-stroke population, allowing them better participation and quality of life. key words: stroke, sensory impairment, perceptual learning, lower limb, clinical trial.


Eligibility criteria:
inclusion criteria: * post stroke * at least 6 months after stroke * with sensory deficits in study's screening tests exclusion criteria: * other neurologic condition * peripheral neuropathy * pacemaker * hemispatial neglect

Keywords: stroke sensory deficit sensory retraining perceptual learning lower extremity
oral axl/mer/csf1r selective tyrosine kinase inhibitor q702 in combination with pembrolizumab in patients with selected advanced solid tumors

Conditions: Esophageal Cancer; Gastric Cancer; Hepatocellular Cancer; Cervical Cancer

Summary: this study is a phase 1b/2 open-label, study to determine safety and preliminary efficacy of q702 in combination with pembrolizumab in study subjects with advanced esophageal, gastric/gej, hepatocellular, and cervical cancers.


Eligibility criteria:
inclusion criteria: * the participant (or legally acceptable representative if applicable) provides written informed consent for the trial. * subjects with histologically or cytologically confirmed advanced or metastatic esophageal, gastric/gej, hepatocellular and cervical cancers who have progressed on treatment with an anti-pd1 or anti pd-l1 monoclonal antibody (mab) administered either as monotherapy, or in combination with other therapies * have measurable disease per recist v 1.1. as assessed by local site investigator/radiology * have an eastern cooperative oncology group (ecog) performance status 0 or 1 * life expectancy of at least 3 months exclusion criteria: * a wocbp who has a positive urine pregnancy test (within 72 hours) prior to treatment or breast-feeding women * concomitant use of strong inhibitors and inducers of cyp1a2, 2j2, 2c19, 2d6, and 3a4/5 within the timeline duration of five half-lives prior to starting study drug and throughout the trial * concomitant use of sensitive substrates of cyp2c9, 2c19, and 3a4 within the timeline duration of five half-lives prior to starting study drug and throughout the trial * has received prior radiotherapy within 2 weeks of start of study treatment or have had a history of radiation pneumonitis * has had an allogeneic tissue/solid organ transplant
idiopathic chronic thrombocytopenia of undetermined significance : pathogenesis and biomarker

Conditions: Thrombocytopenia; Purpura, Thrombocytopenic; Myelodysplastic Syndromes

Summary: it is a translational research study with mechanistical objectives and including biological samples of patients with thrombocytopenia

this study is a prospective study to collect blood, bone marrow and hair bulb from patients with thrombocytopenia, to better understand the mechanism of idiopathic chronic thrombocytopenia of undetermined significance (ictus)

Eligibility criteria:
inclusion criteria: * age: 18-80 * nosological criteria for thrombocytopenic patients: * ictus: acquired thrombocytopenia lasting\>6 months, without feature of dysimmunity (antiplatelet ab, or anti nuclear ab, anti ena ab, anca, anti-ccp ab, cryoglobulinemia), normal bone marrow examination, absence of other thrombocytopenia in the family. all ictus patients included in the study will thus have a bone marrow aspiration. * itp: diagnosis of itp is made according to the international itp consensus (diagnostic criteria of rodeghiero){provan, 2010 #18}, knowing that a presumptive diagnosis of itp is made when the history, physical examination, complete blood count, and examination of the peripheral blood smears do not suggest other etiologies for the thrombocytopenia. there is no "gold standard" test that can reliably establish the diagnosis. we are concerned that this group of patients may include ictus patients. * itp with immunological features: itp with detectable anti-platelet antibodies (ab) and/or autoimmunity (anti nuclear ab, anti ena ab, anca, anti-ccp ab, cryoglobulinemia), and/or previously responsive to immunomodulatory itp-directed therapies (steroids, intravenous immunoglobulin, rituximab, splenectomy). we will use these patients as non-ictus, itp positive controls. * thrombocytopenic myelodysplasia: platelets \<150 g/l and diagnosis of myelodysplasia according to the who classification (abnormal bone marrow features). * healthy controls: patients with normal blood counts undergoing cardiovascular surgery for valve replacement, or healthy bone-marrow donors. * affiliated person or beneficiary of a social security scheme. free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research). exclusion criteria: * age under 18 or over 80 * persons placed under judicial protection, * persons participating in another research including a period of exclusion still in course * persons in emergency situation, * pregnant or nursing women, * women of childbearing age who do not benefit from effective contraception (has criteria), * brain death or deceased persons, * person who doesn't speak french, doesn't read it, doesn't write it, and doesn't have a schooling in france.
cranial electrical stimulation effects on symptoms in persons with fibromyalgia

Conditions: Fibromyalgia

Summary: the purpose of this study is to determine the effects of mild cranial electrical stimulation on pain, fatigue, sleep disturbances, perceived stress, blood pressure, and functional status in persons with fibromyalgia.

central pain networks in the brain are dysregulated in persons with fibromyalgia (fm). thus, the investigators propose that cranial electrical stimulation (ces) that works on the brain may ameliorate symptoms of fm by interacting with the central pain networks. the specific aims of this randomized, controlled, three-group pilot study design are to: (1) determine differences in pain over time between the active ces, sham device, and usual care (uc) groups; (2) explore differences in brain activity in pain processing regions (i.e., cingulate, insula, prefrontal and somatosensory cortices, amygdala, and thalamus) between the active ces, sham device, and uc groups in a subset of 12 participants (6 in each device group); (3) determine the effects of ces on other symptoms (fatigue, sleep disturbances, depression, perceived stress) and functional status, and blood pressure over time between the active ces, sham device, and uc groups; and (4) determine the amount of influence that selected psychological factors (negative affect, catastrophizing, and other personality characteristics) have on group differences in pain, other symptoms, functional status, and brain activity.

Eligibility criteria:
inclusion criteria: * meet the diagnostic criteria for fm established by the american college of rheumatology * have initial pain level equal to or greater than 3 on a nrs 0-10 * have stable medication use related to fm for at least 4 weeks * be able to read, write, and understand the english language exclusion criteria (all participants): * pregnant or breastfeeding * epilepsy or history of seizures * presence of pacemakers and/or other implanted devices exclusion criteria (subset of 12 participants who wil have fmris): * conditions that would not permit an fmri (e.g., certain types of metal or metallic objects in body, diaphragm or intrauterine device, dermal patches, ear or eye implants, implanted electrical stimulators, artificial heart valve, implanted catheter or tube, tattoos, claustrophobia; or weight more than 275 lbs)

Keywords: fibromyalgia pain sleep disturbance fatigue depression functional magnetic resonance imaging
a comparison of intravascular injection with chiba needle and whitacre needle

Conditions: Spinal Stenosis Lumbar; Disk Herniated Lumbar

Summary: caudal epidural injection (cei) is effective for spinal pain. however, intravascular injection may occur during cei, which can lead to hematoma, neurologic deficit and local anesthetics systemic toxicity. whitacre type needle has been reported to be effective for reducing intravascular injection during transforaminal epidural injection. in this study, we compared the chiba needle and whitacre needle on incidence of intravascular injection during cei.

a total of 164 caudal epidural injections were performed in patients with disc herniation or spinal stenosis on lumbosacral region. patients were randomly allocated to group whitacre (n=82) and group chiba (n=82). patients in group whitacre received caudal epidural injection using whitacre type needle and those in group chiba received the procedure using chiba type needle. intravascular injection was assessed with blood aspiration and angiography during real-time fluoroscopy.

Eligibility criteria:
inclusion criteria: * patients with low back pain and/or leg radicular pain under diagnoses as disc herniation or spinal stenosis exclusion criteria: * allergy to local anesthetics or contrast medium, coagulopathy, local infection at the injection site, and systemic infection
effect of radial shockwave on calf muscle spasticity in patients with cerebral palsy

Conditions: Cerebral Palsy

Summary: the aim of this study to assess different outcome measures after applying standard physical therapy plus radial shockwave and compare the results with another group who received standard treatment only. design: double-blinded (assessor and data analyzer) methods: this study will be conducted in 4 rehabilitation facilities, times for 1 month of intervention assessment timeline: 3 times (t0: at baseline, t1: at 4 weeks, t2: follow up at 3 months. outcome measures: the modified ashworth scale (mas), ankle rom, plantar surface area, gross motor function, and quality of life

the current study is a randomized controlled trial in which the researchers intended to examine the effect of adding radial shockwave therapy to standard physical therapy on the status of calf muscle spasticity and consequent effects on gross motor function, ankle joint rom, plantar surface area, and quality of life. the experimental intervention will consist of 4 sessions of radial shockwave applied to the bulkiest area of the calf muscle in children having spastic cerebral palsy. participants will receive 1 session of radial shockwave per week and will continue their regular physical therapy as usual (3 sessions per week). outcome assessment will be conducted 3 times: at baseline, after the end of the treatment program, and at 3 months follow-up. the tools that will be used to collect data will be: 1. modified ashworth scale for muscle tone. 2. goniometer for ankle rom. 3. emed force platform for plantar surface area 4. gross motor function scale for gross motor function 5. cerebral palsy quality of life questionnaire for quality of life assessment

Eligibility criteria:
inclusion criteria: * age between 8-14 * diagnosed with spastic cp * ability to walk alone or with assistance * grades 1 -4 on gross motor function classification system * at least score 1 on the modified ashworth scale (mas) * ability to attend the treatment program and the outcome assessment sessions. exclusion criteria: * patients who received a botulinum toxin injection in the calf muscle during the last six months * structural contracture of the calf muscle * surgery in the lower extremity during the previous year * those experiencing pain in the lower limbs * severe associated neurological diseases as epilepsy * medications affecting peripheral muscle tone.

Keywords: radial shockwave therapy muscle tone rom gross motor scale quality of life
work hour reductions, medical errors, and intern well-being at providence st. vincent medical center intensive care unit

Conditions: Sleep Deprivation; Depression

Summary: the purpose of this study is to determine whether reducing intern work hours and eliminating extended shifts in the intensive care unit will reduce prescribing errors and improve intern well-being.

each intern enrolled will complete three 4-week rotations in the intensive care unit (icu) at providence st. vincent medical center. each intern will complete at least one traditional schedule and one intervention schedule. the traditional schedule consists of an 80-hour work week with overnight call every third night. the longest shift on the traditional schedule is 30 hours. the intervention schedule consists of a 60-hour work week which eliminates overnight call by assigning a variety of shifts ranging from 8 to 16 hours in length.

Eligibility criteria:
inclusion criteria: * interns rotating at providence st. vincent medical center icu exclusion criteria: * diagnosis of narcolepsy

Keywords: internship and residency medical errors burnout, professional burnout depression actigraphy personnel staffing and scheduling sleep deprivation workload humans adult male female intensive care units prospective studies crossover studies work schedule tolerance disorders of excessive somnolence guideline adherence internal medicine education
impact of savr and tavr on patient's activity and mobility

Conditions: Aortic Valve Stenosis

Summary: this is an independent, investigator-initiated, prospective multicenter observational study with restricted grant provided by edwards lifesciences that aims to describe baseline (preoperative) physical function and to assess and compare 6-month postoperative changes in the physical function of patients undergoing aortic stenosis (as) treatment with either transcatheter aortic valve replacement (tavr) or surgical aortic valve replacement (savr) implanted with edwards valve type ("sapien 3" and "sapien xt" for tavr; "inspiris resilia", "edwards intuity" and "carpentier-edwards perimount magna-ease" for savr). secondary objectives of this study are: to evaluate the validity of wearable devices in assessing physical function in such patients and subjects' compliance in wearing the device also after a very long follow-up time up to 12 months; to assess and compare 6-month postoperative changes in health-related quality of life (hrqol), sleep quality, cognitive function of patients undergoing as treatment with either tavr or savr. smart watch activity tracker "vívoactive® hr" devices by "garmin©" will be used in the study. devices will be distributed to the patients at time of baseline assessment, along with a bluetooth-paired smartphone provided with a prepaid data-only sim-card and study-customised interface. patients will be asked to wear the device 24 hours a day, 7 days a week, from the baseline assessment to the last follow-up, 12 months after baseline.


Eligibility criteria:
inclusion criteria: * severe native aortic valve stenosis symptomatic for heart failure or angina; * indication to isolated tavr or savr given by heart team; * tavr through the trans-femoral approach; * savr by any access; * implantation of an edwards valve type (sapien 3 and sapien xt for tavr; inspiris resilia, edwards intuity and carpentier-edwards perimount magna-ease for savr); * signed informed consent. exclusion criteria: * use of walking aids; * dyskinesia or parkinson's disease; * reduced survival expectancy due to severe co-morbidities (\<1 year); * lack of any of inclusion criteria.

Keywords: savr tavr physical function aortic valve replacement wearable devices smart watch activity tracker
a study of ziprasidone for the treatment of psychosis in patients who had already had benefits from ziprasidone treatment in a previous study

Conditions: Pyschotic Disorders

Summary: the purpose of this study is to evaluate the efficacy and tolerability of ziprasidone in patients who successfully completed a study of ziprasidone treatment of psychosis (protocol a1281074).


Eligibility criteria:
inclusion criteria: * psychotic disorder * completion of previous study of intramuscular ziprasidone * ability to continue with oral ziprasidone exclusion criteria: * concomitant treatment with other anti-psychotic agents within 12 hours prior to the enrollment; for depot agents, a period of two weeks or a cycle, whichever is longer, should occur between the last administration and the patient's enrollment. * treatment with antidepressants or mood stabilizers within seven days prior to the enrollment; for maois (monoamine oxidase inhibitors) and moclobemide, this period should be of two weeks; for fluoxetine, five weeks. * resistance to conventional psychotic agents. (resistance is defined as a failure to present a therapeutic response during the acute exacerbation after proper attempts of treatment with marketed antipsychotic agents in two or more occasions during the two years prior to the enrollment in the study.)
washed microbiota transplantation for malnutrition

Conditions: Malnutrition

Summary: malnutrition is a pathological condition in which dietary intake fails to meet the body's energetic or nutritional needs. it may be caused by macronutrient or micronutrient deficiencies, high energy expenditure, impaired nutrient absorption or assimilation. malnutrition can affect all stages of life. in adults, malnutrition is strongly associated with poor clinical outcomes such as increased morbidity, increased mortality and prolonged hospitalization. in children, malnutrition can lead to growth retardation, cognitive impairment and immune dysfunction.

the gut microbiota of malnourished patients is different from that of healthy people. the diversity of the gut microbiota of patients with severe malnutrition reduced and the abundance of proteobacteria significantly increased, as well as pathogenic genera such as klebsiella, escherichia coli, shigella, and streptococcus. this suggests that gut microbiota plays an important role in the occurrence and development of malnutrition. dietary intervention targeting gut microbiota can quickly improve children's malnutrition, promote weight gain and increase protein levels that promote bone growth and nerve development. exclusive enteral nutrition combined with immediate washed microbiota transplantation(wmt) can rapidly improve the nutritional status of patients with crohn's disease compared with those with delayed wmt. gut microbiota has been confirmed to be closely related to malnutrition. improving the disordered gut microbiota in malnourished patients may become a potential treatment.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years old; 2. meet any of the following two conditions: ①weight loss (\>5% weight loss in the past 6 months or \>10% weight loss in more than 6 months); ②low bmi (\<70 years old and bmi\<18.5kg/m2 or ≥70 years old and bmi\<22kg/m2); 3. underwent washed microbiota transplantation. exclusion criteria: 1. expected survival time \<3 months; 2. women who are pregnant or breastfeeding; 3. other patients deemed not suitable for enrollment by the investigator.

Keywords: washed microbiota transplantation malnutrition fecal microbiota transplantation
a study of orforglipron in adult participants with obesity or overweight and type 2 diabetes

Conditions: Obesity; Overweight; Type 2 Diabetes

Summary: this study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. the study will last about 77 weeks and may include up to 22 visits.


Eligibility criteria:
inclusion criteria: * have a body mass index (bmi) ≥27.0 kilogram/square meter (kg/m²). * have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight. * have a diagnosis of type 2 diabetes (t2d), with hba1c ≥7% (≥53 mmol/mol) to ≤10% (86 mmol/mol) and are on stable treatment for t2d for at least 90 days prior to screening, consisting of: * either diet/exercise alone or * up to 3 oral antihyperglycemic medications (excluding dipeptidyl peptidase iv inhibitors (dpp-4i) or glucagon-like peptide-1 (glp-1) receptor agonists (ra). exclusion criteria: * have type 1 diabetes (t1d), history of ketoacidosis or hyperosmolar state/coma, or any other types of diabetes except t2d. * have a self-reported change in body weight \>5 kg (11 pounds) within 90 days prior to screening. * are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema (for example, laster photocoagulation or intravitreal injections of anti-vascular endothelial growth factor inhibitors). * have family (first-degree relative) or personal history of medullary thyroid cancer (mtc) or multiple endocrine neoplasia 2 (men2) syndrome. * have had a history of chronic or acute pancreatitis.